Delving into the Latest Updates on Enalapril Maleate/Lercanidipine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Atover, Carmen ACE, Coripren

+ [9]

Target

ACE x VDCCs

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization

Recordati SpA

Active Organization

Viatris Pty Ltd.

Recordati SpA

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (14 Feb 2008),

Hypertension

Regulation-

Login to view timeline

Structure

Molecular FormulaC36H42ClN3O6

InChIKeyWMFYOYKPJLRMJI-UHFFFAOYSA-N

CAS Registry132866-11-6

View All Structures (2)

Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not achieving blood pressure. Several studies have shown that use of fixed combinations improve compliance significantly, by reducing the number of pill's intake.
This study will assess the antihypertensive efficacy of Vasodip-Combo 20® [enalapril 20 mg + lercanidipine 10 mg] as a fixed combination drug in uncontrolled antihypertensive patients.

Start Date01 Jan 2011

Sponsor / Collaborator

Meir Medical Center

[+1]

NCT01093807 / CompletedPhase 2

Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension

The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

Start Date01 Mar 2010

Sponsor / Collaborator-

100 Clinical Results associated with Enalapril Maleate/Lercanidipine Hydrochloride

Login to view more data

100 Translational Medicine associated with Enalapril Maleate/Lercanidipine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Enalapril Maleate/Lercanidipine Hydrochloride

Login to view more data

49

Literatures (Medical) associated with Enalapril Maleate/Lercanidipine Hydrochloride

24 Jan 2024·ACS Applied Materials & Interfaces

Heteromultivalent Ligand Display on Reversible Self-Assembled Monolayers (rSAMs): A Fluidic Platform for Tunable Influenza Virus Recognition

Article

Author: Sellergren, Börje ; Yeung, Sing Yee ; Sergeeva, Yulia

We report on the design of heteromultivalent influenza A virus (IAV) receptors based on reversible self-assembled monolayers (SAMs) featuring two distinct mobile ligands. The principal layer building blocks consist of α-(4-amidinophenoxy)alkanes decorated at the ω-position with sialic acid (SA) and the neuraminidase inhibitor Zanamivir (Zan), acting as two mobile ligands binding to the complementary receptors hemagglutinin (HA) and neuraminidase (NA) on the virus surface. From ternary amphiphile mixtures comprising these ligands, the amidines spontaneously self-assemble on top of carboxylic acid-terminated SAMs to form reversible mixed monolayers (rSAMs) that are easily tunable with respect to the ligand ratio. We show that this results in the ability to construct surfaces featuring a very strong affinity for the surface proteins and specific virus subtypes. Hence, an rSAM prepared from solutions containing 15% SA and 10% Zan showed an exceptionally high affinity and selectivity for the avian IAV H7N9 (K_d = 11 fM) that strongly exceeded the affinity for other subtypes (H3N2, H5N1, H1N1). Changing the SA/Zan ratio resulted in changes in the relative preference between the four tested subtypes, suggesting this to be a key parameter for rapid adjustments of both virus affinity and selectivity.

01 Jan 2024·Therapeutic Advances in Medical Oncology

Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia

Article

Author: Reczek, Monika ; Monica, Magdalena ; Kawalec, Paweł

Background: The recent development of new antileukemic therapies (anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhbitors, phosphoinositide 3-kinase inhibitors, and B-cell lymyphoma-2 antagonists) improved the progression-free survival (PFS) compared with selected standard regimens in clinical trials for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Unfortunately, the relative efficacy of all possible therapeutic options remains unknown because there is no direct evidence for all possible comparisons. Objectives: We aimed to compare the efficacy and safety of novel agents, chemotherapy, and immunotherapy using a Bayesian network meta-analysis (NMA). Design: Systematic literature review with Bayesian NMA. Methods: An extensive systematic literature review of randomized clinical trials for relapsed/refractory CLL was performed. We searched for articles indexed in medical databases (MEDLINE, Embase, The Cochrane Library) and gray literature that could be further implemented into the Bayesian NMA. Results: The systematic search identified 15 randomized trials that formed networks comparing PFS, overall survival (OS), overall response rates, and serious adverse events. Our study showed that all regimens containing novel agents significantly prolonged PFS compared with standard chemoimmunotherapy and immunotherapy. Among targeted drugs, venetoclax (VEN) + rituximab (RTX) had comparable efficacy in terms of PFS to zanubrutinib (ZAN) [hazard ratio (95% credible interval), 1.10 (0.59–2.08)], acalabrutinib (ACA) [0.78 (0.47–1.30)], ibrutinib (IBR) monotherapy [0.72 (0.41–1.27)], and other IBR-based regimens. ZAN was superior to IBR monotherapy [0.65 (0.49–0.86)] but not to ACA [0.71 (0.49–1.02)]. There were no significant differences in OS in any of the above comparisons. Conclusion: All novel therapies have better efficacy than chemoimmunotherapy and immunotherapy regimens. Among novel agents, the relative efficacy of VEN + RTX was similar to all BTKi, while ZAN was superior to IBR and comparable to ACA. Trial registration: PROSPERO CRD42022304330.

01 Jan 2024·Asian Pacific Journal of Allergy and Immunology

A new pepper allergen Zan b 1.01 of 2S albumins: Identification, cloning, characterization, and cross-reactivity

Article

Author: Liu, Siyu ; Zhu, Liping ; Hu, Jing ; Tang, Rui ; Zhang, Yuzhu ; Ni, Kang ; Sun, Jing-Lyu ; Ye, Xiaodong ; Jin, Tengchuan ; Ma, Li ; Li, Hong ; Chen, Feng ; Wang, Rui-Qi ; Zhu, Lixia

BACKGROUNDZanthoxylum bungeanum (Sichuan pepper; in Chinese) is used as a spice worldwide and is a potentially life-threatening allergenic food source, as first reported by our team in 2005. However, its allergen components are unknown.OBJECTIVEWe aim to identify and characterize its major allergen and determine its cross-reactivities with citrus seeds, pistachios, and cashew seeds.METHODSIonic exchange and molecular exclusion chromatography were used to isolate the protein components from Sichuan pepper seed. A protein fraction was characterized by SDS-PAGE, analytical ultracentrifugation, mass spectrometry, and circular dichroism spectroscopy. The coding region of it was amplified from the genome. ELISA and competitive ELISA assays were used to investigate the allergenicity and cross-reactivity of allergens.RESULTSThis protein allergen was around 14 kDa. It was a 2S albumin similar to an α-Amylase inhibitor (AAI) domain-containing protein of Citrus sinensis. Circular dichroism spectroscopy showed its thermal stability was high. A 303 bps DNA sequence of the AAI domain was cloned from the genome of the Sichuan pepper. Competitive ELISA assays showed positive cross-reactivities between this allergen and citrus seeds, pistachios, and cashew seeds.CONCLUSIONA major allergen of around 14 kDa from Sichuan pepper seed was confirmed, which belongs to the 2S albumin of plant seed storage proteins. Based on the nomenclature of the IUIS Subcommittee for Allergen Nomenclature, this allergen is designated as Zan b 1.01. The cross-reactivities were demonstrated between Zan b 1.01 and citrus seeds, pistachios, and cashew seeds.

100 Deals associated with Enalapril Maleate/Lercanidipine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09BB02	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	AU	Viatris Pty Ltd.	14 Feb 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01093807 (Pubmed \| J Hypertens)	Phase 2	Hypertension	1,039	Placebo	xkvlnzkltm(milmxwnhuv) = nzcpzolxbu xappcthsyl (kanebfakqc ) View more	-	01 Jan 2016
				Lercanidipine 10mg	xkvlnzkltm(milmxwnhuv) = vsegssoenc xappcthsyl (kanebfakqc ) View more